February 8, 2018Clinical Microbiology and InfectionOpen Access

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

View Full Paper

Ask AI

Bookmark

Abstract

The overall benefit-risk remained positive in those aged ≥9 years up to year 4, although the protective effect was lower in years 3 and 4 than in years 1 and 2.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Arredondo-Garcı́a et al. (2018) studied this question.

synapsesocial.com/papers/69dd0a2f61d4dd8dbb13330a https://doi.org/10.1016/j.cmi.2018.01.018

View Full Paper

Ask AI

Bookmark

Abstract

The overall benefit-risk remained positive in those aged ≥9 years up to year 4, although the protective effect was lower in years 3 and 4 than in years 1 and 2.

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

Abstract

Discussion

Cite This Study

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

Abstract

Discussion

Cite This Study

Keep reading

Keep reading